GenExel is a functional genomics company
specializing in rapid disease gene target discovery and validation
for drugs to treat a wide spectrum of human diseases.
The Company utilizes the unmatched power of model organism genetics
to select priority candidate drug targets from the sea of genomic
information.
GenExel has industrialized the world's largest and most comprehensive
system to interrogate an animal genome and identify functionally
relevant genes within human disease gene-associated networks,
thus greatly accelerating the pace of rational drug design and
development.
Discovering
new disease genes, gene interactions and
gene functions
Determining
compound modes of action
The resulting information can identify and validate
targets for new drug design and provide new understanding of genetic
pathways involved in an array of diseases.
Scope
GenExel's fly stock library comprises nearly 25,000 mutant lines selected from 100,000 independent EP stocks, providing extensive genome coverage
Speed
Genetic screens are rapid and high-throughput
Cost
Screens are far less expensive than in mammalian systems
Relevance
Screens are performed in a complex, living animal,
thus candidate target genes are biologically relevant
Versatility
Genetic interaction screens can be performed for any human disease gene of interest and can be surveyed in multiple tissue types
